Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.1 CAD | -0.47% | 0.00% | -22.22% |
17/04 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
17/04 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 78.31 | 123.8 | 93.89 | 160.9 | 146.8 | - | - |
Enterprise Value (EV) 1 | 78.31 | 123.8 | 93.89 | 160.9 | 146.8 | 146.8 | 146.8 |
P/E ratio | -6.37 x | - | - | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | -14.1 x | -4.66 x | -13.9 x | -6.81 x | -4.71 x | -4.58 x |
EV / FCF | - | -15 x | -5.27 x | - | -9.86 x | -6.67 x | - |
FCF Yield | - | -6.68% | -19% | - | -10.1% | -15% | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 35,117 | 45,362 | 58,679 | 59,606 | 69,928 | - | - |
Reference price 2 | 2.230 | 2.730 | 1.600 | 2.700 | 2.100 | 2.100 | 2.100 |
Announcement Date | 08/04/21 | 28/02/22 | 30/03/23 | 17/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | -8.753 | -20.13 | -11.59 | -21.58 | -31.16 | -32.09 |
EBIT | - | -12.81 | -23.03 | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - |
Net income | -11.19 | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - |
EPS | -0.3500 | - | - | - | - | - | - |
Free Cash Flow 1 | - | -8.272 | -17.81 | - | -14.9 | -22 | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 08/04/21 | 28/02/22 | 30/03/23 | 17/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -3.656 | -3.059 | -4.196 | -5.448 | -4.279 | -6.212 | -4.5 | -6.2 | -5.6 | -5.3 |
EBIT | -3.667 | -4.147 | -5.004 | -6.313 | -4.924 | -6.784 | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | -3.599 | - | - | - | - | - | - | - | - | - |
Net income | -3.599 | - | - | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - |
EPS | -0.0900 | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 18/11/21 | 28/02/22 | 12/05/22 | 10/08/22 | 14/11/22 | 30/03/23 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -8.27 | -17.8 | - | -14.9 | -22 | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 0.13 | 0.24 | 0.25 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 08/04/21 | 28/02/22 | 30/03/23 | 17/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.22% | 11Cr | |
+29.77% | 4.92TCr | |
+1.00% | 4.21TCr | |
+50.47% | 4.04TCr | |
-5.26% | 2.89TCr | |
+13.68% | 2.61TCr | |
-22.99% | 1.87TCr | |
+8.22% | 1.33TCr | |
+32.41% | 1.23TCr | |
-1.62% | 1.2TCr |
- Stock Market
- Equities
- NGEN Stock
- Financials NervGen Pharma Corp.